News Details

View all news

Mirati Therapeutics and MethylGene Announce Completion of Plan of Arrangement

San Diego, California and Montreal, Canada, June 28, 2013

The Arrangement was overwhelmingly approved by shareholders of MethylGene at the Annual and Special meeting held on June 25, 2013. The Ontario Superior Court of Justice (Commercial List) issued a final order approving the Arrangement on Thursday, June 27, 2013.

Mirati Therapeutics will base its headquarters in San Diego, California, with offices in Princeton, New Jersey and Montreal, Canada.

“This is a pivotal step in the evolution of our company and the advancement of our programs in targeted oncology”, said Dr. Charles Baum, President and Chief Executive Officer of Mirati Therapeutics. “As a U.S. corporation, Mirati Therapeutics has the best opportunity to bring novel therapeutics to oncology patients and significantly increase the value of the company.”

Mirati Therapeutics is a publicly-traded biopharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer. Our compounds result from internal chemistry efforts targeting the active sites of enzymes that are key drivers of tumor growth. Our clinical development programs are focused on treating selected tumor types that express high levels of these targets in order to most effectively address unmet patient needs. Our lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. We are also evaluating development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor and MGCD516, a kinase inhibitor with a distinct target profile.

This news release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any securities.

Investor Relations Contacts

Mark J. Gergen
Executive Vice President & COO
Mirati Therapeutics, Inc.
Tel.: 858.535.2075

Michael Wood
Managing Director
LifeSci Advisors
Tel.: 646.597.6983

Tracey Rowlands, PhD
Director of Investor Relations and Business Development
Mirati Therapeutics, Inc.
Tel.: 514.337.3333 ext. 512

Categories: Press Releases
View all news